Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
By C. Tam, S. O'brien, W. Wierda, H. Kantarjian, S. Wen, K. Do, D. Thomas, J. Cortes, S. Lerner, M. Keating. Blood, 2008
739 citations recorded by the source corpus.
Subfields: Genetics, Immunology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/2cc986722e04b0e753668adad2497da83824deb4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Elizabeth Bilotti
- Yun Shaw
- Cathy Zhou
Citations in the corpus
- Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. (2014, neutral): “(%) 16/203 (8) 10/96 (10) 9/196 (5) 10/97 (10) 22/295 (7) 20/287 (7)”
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. (2016, neutral): “Richter’s transformation 38 (28) 38 (5) 25 (33) 25 (6) 13 (22) 13 (3)”
- Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. (2015, background): “3 years 10 (32) 13 (13) 23 (17) Grade ‡3 AEs”